JP2024523730A - 天然のライアビリティを含まないｃｄｒを使用した抗体親和性成熟 - Google Patents

天然のライアビリティを含まないｃｄｒを使用した抗体親和性成熟 Download PDF

Info

Publication number
JP2024523730A
JP2024523730A JP2024501196A JP2024501196A JP2024523730A JP 2024523730 A JP2024523730 A JP 2024523730A JP 2024501196 A JP2024501196 A JP 2024501196A JP 2024501196 A JP2024501196 A JP 2024501196A JP 2024523730 A JP2024523730 A JP 2024523730A
Authority
JP
Japan
Prior art keywords
antibody
cdr sequences
sequence
cdr3
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523730A5 (enExample
Inventor
レイモン モートン ブラッドバリー アンドリュー
ディアンジェロ サラ
テイシェイラ アンドレ
Original Assignee
ルールズ－ベースド メディシン インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルールズ－ベースド メディシン インコーポレイティド filed Critical ルールズ－ベースド メディシン インコーポレイティド
Publication of JP2024523730A publication Critical patent/JP2024523730A/ja
Publication of JP2024523730A5 publication Critical patent/JP2024523730A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
JP2024501196A 2021-07-07 2022-07-07 天然のライアビリティを含まないｃｄｒを使用した抗体親和性成熟 Pending JP2024523730A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218919P 2021-07-07 2021-07-07
US63/218,919 2021-07-07
PCT/US2022/036422 WO2023283383A1 (en) 2021-07-07 2022-07-07 Antibody affinity maturation using natural liability-free cdrs

Publications (2)

Publication Number Publication Date
JP2024523730A true JP2024523730A (ja) 2024-06-28
JP2024523730A5 JP2024523730A5 (enExample) 2025-07-14

Family

ID=84801095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501196A Pending JP2024523730A (ja) 2021-07-07 2022-07-07 天然のライアビリティを含まないｃｄｒを使用した抗体親和性成熟

Country Status (6)

Country Link
US (2) US20230167165A1 (enExample)
EP (1) EP4366773A4 (enExample)
JP (1) JP2024523730A (enExample)
KR (1) KR20240056488A (enExample)
CN (1) CN118103065A (enExample)
WO (1) WO2023283383A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3246434A1 (en) * 2015-01-13 2017-11-22 Ewha University-Industry Collaboration Foundation Method for preparing novel antibody library and library prepared thereby
EP3728705A4 (en) * 2017-12-18 2022-01-19 Charles River Laboratories, Inc. RADICALLY DIVERSE HUMAN ANTIBODY LIBRARY
EP3833685A4 (en) * 2018-07-08 2022-08-17 Specifica Inc. ANTIBODY LIBRARIES WITH FEATURES FOR MAXIMIZED ANTIBODY DEVELOPMENT

Also Published As

Publication number Publication date
US20230167165A1 (en) 2023-06-01
EP4366773A1 (en) 2024-05-15
WO2023283383A1 (en) 2023-01-12
CN118103065A (zh) 2024-05-28
EP4366773A4 (en) 2025-11-05
US20240384438A1 (en) 2024-11-21
KR20240056488A (ko) 2024-04-30

Similar Documents

Publication Publication Date Title
Shi et al. De novo selection of high-affinity antibodies from synthetic fab libraries displayed on phage as pIX fusion proteins
Wark et al. Latest technologies for the enhancement of antibody affinity
JP5791496B2 (ja) 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
US20240240360A1 (en) Antibody libraries with maximized antibody developability characteristics
JP2014077004A (ja) 多様な合成ペプチドおよびポリペプチドライブラリーの設計および構築
Teixeira et al. Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs
US20250020659A1 (en) Single domain antibody libraries with maximized antibody developability characteristics
US20240384438A1 (en) Antibody affinity maturation using natural liability-free cdrs
CN112424221B (zh) 抗体文库和使用抗体文库的抗体筛选方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250704